ITPP

ITPP, also known as myo-inositol trispyrophosphate or OXY111A, is an experimental compound investigated for oxygen delivery and metabolic performance. The cited clinical study concerns a hypoxia modifier in hepatopancreatobiliary tumors. The weight-management claims, weekly schedules and GLP-1-style safety categories below lack compound-specific support in these citations; they should not be interpreted as established ITPP effects or treatment guidance.

• Weight Loss

  Most effective

  Sustained reductions in body weight are claimed, but the cited ITPP studies do not establish this indication.

• Blood Sugar Control

  Most effective

  Improved A1C and glucose control in type 2 diabetes are proposed without supporting ITPP evidence in the cited studies.

• Cardiovascular Health

  Effective

  Fewer cardiovascular events in higher-risk patients are claimed without compound-specific substantiation for ITPP.

• Metabolic Syndrome

  Effective

  Effects across several features of metabolic syndrome are proposed but remain unsupported by the cited ITPP evidence.

• GLP-1 agonists (semaglutide, tirzepatide)

  Avoid

• Insulin

  Monitor

• Sulfonylureas

  Monitor

• Metformin

  Compatible

• SGLT2 Inhibitors

  Compatible

• Oral Contraceptives

  Caution

• Warfarin / Blood Thinners

  Monitor

• NAD+

  Compatible

Diluent: Use bacteriostatic water only; avoid saline because precipitation can occur.

1. Let the refrigerated vial warm to room temperature for 15–20 minutes before preparing it.
2. Disinfect the stopper using an alcohol swab, then wait until the surface has dried fully in the air.
3. Use a sterile syringe to measure your calculated amount of bacteriostatic water. Use this diluent only; avoid saline because precipitation may occur.
4. Introduce the water gradually against the inner glass wall. Keep the stream away from the peptide powder itself.
5. Rotate the vial gently to mix its contents. Do not shake forcefully, because vigorous agitation can degrade the peptide.
6. Wait 2–3 minutes for the powder to dissolve completely. Check that the liquid is transparent and has no color.
7. Measure your calculated dose with an insulin syringe in preparation for administration beneath the skin.
8. Use the abdomen, thigh or upper arm for subcutaneous administration. Change the injection location each time to help prevent lipodystrophy.
9. Return the mixed vial to refrigeration at 2–8°C. Use the prepared solution within 28 days of mixing.

Week 1–2

The proposed early pattern includes less appetite and mild digestive symptoms such as nausea or fullness while adapting.

Week 2–4

The proposed pattern includes fewer food cravings, smaller portions and early changes in weight.

Week 4–8

The proposed pattern includes stronger appetite control, continuing weight reduction and better glucose control where relevant.

Week 8–16

The proposed pattern includes substantial weight reduction, improved energy and early improvement in metabolic markers.

Week 16–24

The proposed pattern includes a larger weight-loss milestone, cardiovascular benefit and changes in blood lipids.

Week 24+

The proposed pattern includes peak efficacy with broader metabolic improvement and sustained effects. These GLP-1-style expectations are not established ITPP outcomes by the cited evidence.

• Nausea that is usually temporary and varies with dose · Most common
• Constipation or diarrhea while increasing the dose
• Vomiting, particularly at initiation or after an increase
• Lower appetite and feeling full earlier
• Bruising or redness at the administration site
• Tiredness, especially during the initial weeks
• Pancreatitis; stop immediately if severe abdominal pain develops · Rare
• Effects on thyroid C-cells; avoid with MEN2 or a thyroid cancer history · Rare

Contraindications

• MEN2 or a history of thyroid cancer; this GLP-1-style restriction is not substantiated for ITPP by the cited studies.

ITPP: not approved in the US.

• US

  Not approved

  FDA — experimental use only, without therapeutic approval. The regulatory record indicates no prescription requirement, no 503A ban and no applicable telehealth pathway.

  Rx required

  No

  Telehealth

  N/A

1. Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors. (2021)

   PMID 34155211DOI 10.1038/s41467-021-24069-w

2. Effects of OXY111A (Myo-inositol trispyrophosphate) in Hepato-Pancreato-Biliary Neoplasms (NCT02528526) (2015)